ultomiri start take reign
top bottom line beat guidanc rais
report revenu consensu driven strong
soliri perform note includ neg impact foreign
exchang rate favor impact tender order certain non-u
market non-gaap ep came consensu driven higher
expect soliri revenu lower expect cost up
revenu guidanc includ soliris/ultomiri
sale also increas bottom line guidanc rais ep
estim accordingli note guidanc includ price headwind
 fx headwind maintain buy alxn strong underli busi
ultomiri first full quarter market convert us pnh patient
treat soliri result sale ahead schedul alxn
target two-year convers rate april us patient
convert enrol onesourc alxn abil execut convers
target could critic protect complement franchis competit
believ discount ultomiri compar soliri pnh mainten
phase discount ahu gmg continu facilit convers
strensiq kanuma price adjust increas volum
sale strensiq kanuma year-over-
year note howev volum year-over-year indic
approxim lower net price made strateg decis lower price
increas patient access reinvigor sale growth metabol franchis
alxn next major catalyst june pdufa approv date soliri nmosd
signific market help alxn shift focu rare neurolog
disord submit applic us approv ultomiri ahu
april anticip launch earli first patient dose phase
trial ultomiri gmg phase subcutan ultomiri formul
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biotechnolog compani market
soliri monoclon antibodi therapi
treatment ultra-rar diseas includ
paroxysm nocturn hemoglobinuria pnh
compani also market strensiq treatment
hypophosphatasia kanuma lal-d
focu sever life threaten ultra rare
rate buy expect industri
growth compani market product soliri
success launch new product
strensiq kanuma see upsid risk street
estim addit pipelin
momentum creat news flow
price object base discount cash flow analysi use
wacc termin growth rate
downsid risk failur meet expect soliri sale and/or launch
strensiq asfotas alfa kanuma lal-d govern drug price
focu ultra-orphan product failur advanc key pipelin product includ
soliri new indic
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
qualiti earn
